Haematologica EWOG-MDS website
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

Published online 20 February 2008
Haematologica, Vol 93, Issue 3, 447-450 doi:10.3324/haematol.11934
Copyright © 2008 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Hauswirth et al. Supplementary Appendix
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hauswirth, A. W.
Right arrow Articles by Jäger, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hauswirth, A. W.
Right arrow Articles by Jäger, U.

Malignant Lymphomas

Autoimmune thrombocytopenia in non-Hodgkin’s lymphomas

Alexander W. Hauswirth1,, Cathrin Skrabs1, Christian Schützinger1, Markus Raderer2, Andreas Chott3, Peter Valent1, Klaus Lechner1, Ulrich Jäger1

1 Department of Medicine I, Division of Hematology and Hemostaseology and
2 Oncology
3 Department of Pathology, Medical University of Vienna, Vienna, Austria

Correspondence: Alexander Hauswirth, Department of Medicine I, Division of Haematology and Haemostaseology, Medical University of Vienna, Vienna, A 1090 Währingergürtel 18– 20, Austria. E-mail: alexander.hauswirth{at}meduniwien.ac.at

Autoimmune thrombocytopenia is a common immunehematologic complication in non-Hodgkin’s lymphomas and may complicate the treatment. We analyzed an original series from our institute as well as published cases of non-Hodgkin’s lymphomas (excluding chronic lymphocytic leukemia) associated with autoimmune thrombocytopenia with regard to demographic factors, prevalence in non-Hodgkin’s lymphoma subtypes and treatment outcome. The male/female ratio is 1.75. Half of the cases occurred prior to diagnosis of lymphoma. Chemotherapy is the best treatment in many non-Hodgkin’s lymphomas patients with autoimmune thrombocytopenia compared with standard treatment of autoimmune thrombocytopenia. Splenectomy is effective in splenic marginal zone lymphoma. Autoimmune thrombocytopenia in patients with non-Hodgkin’s lymphomas is potentially life-threatening and difficult to treat.

Key words: autoimmune thrombocytopenias, non-Hodgkin’s lymphoma.






HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2008 by the Ferrata Storti Foundation.